Novel agents for KRAS-mutant NSCLC

被引：0
|
作者：
Janne, Pasi A. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.477
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY20-1
引用
收藏
页码：S444 / S444
页数：1
相关论文
共 50 条
  • [1] Sotorasib effective in KRAS-mutant NSCLC
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (08) : 470 - 470
  • [2] Sotorasib effective in KRAS-mutant NSCLC
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2021, 18 : 470 - 470
  • [3] A step towards treating KRAS-mutant NSCLC
    Goldberg, Sarah B.
    Schlessinger, Joseph
    Boyer, Julie L.
    Herbst, Roy S.
    LANCET ONCOLOGY, 2013, 14 (01): : 3 - 5
  • [4] Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
    Garrido, Pilar
    Eugenia Olmedo, Maria
    Gomez, Ana
    Paz Ares, Luis
    Lopez-Rios, Fernando
    Manuel Rosa-Rosa, Juan
    Palacios, Jose
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (09) : 589 - 597
  • [5] Treating KRAS-Mutant Lung Cancer With Combination Agents
    Shumeyko, Emma P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (04) : 315 - 315
  • [6] Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
    Liu, Weiran
    Yin, Yuesong
    Wang, Jun
    Shi, Bowen
    Zhang, Lianmin
    Qian, Dong
    Li, Chenguang
    Zhang, Hua
    Wang, Shengguang
    Zhu, Jinfang
    Gao, Liuwei
    Zhang, Qiang
    Jia, Bin
    Hao, Ligang
    Wang, Changli
    Zhang, Bin
    ONCOTARGET, 2017, 8 (01) : 179 - 190
  • [7] A novel combination strategy to treat KRAS-mutant lung cancer
    Peng, R. -W.
    Liang, S. -Q.
    Buhrer, E. D.
    Berezowska, S.
    Marti, T. M.
    Froment, L.
    Yang, H.
    Hall, S. R.
    Vassella, E.
    Yang, Z.
    Kocher, G. J.
    Amrein, M. J.
    Riether, C.
    Ochsenbein, A. F.
    Schmid, R. A.
    BRITISH JOURNAL OF SURGERY, 2019, 106 : 19 - 19
  • [8] Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC
    Maione, Paolo
    Sgambato, Assunta
    Rossi, Antonio
    Sacco, Paola Claudia
    Bareschino, Maria Anna
    Schettino, Clorinda
    Casaluce, Francesca
    Ciardiello, Fortunato
    Gridelli, Cesare
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (02) : 93 - 100
  • [9] Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
    Xia, Meng
    Li, Xuena
    Diao, Yao
    Du, Bulin
    Li, Yaming
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [10] Gene signature of KRAS-mutant cancers
    Kabashima, Kenji
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (10) : 2110 - 2110
12345